Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
BMO Capital Reiterates Outperform on Bristol-Myers Squibb (BMY)
January 25, 2019 8:45 AM ESTBMO Capital analyst, Alex Arfaei, reiterated an Outperform rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) following the company's 4Q earnings report. Arfaei remains comfortable with Bristol's independent business: from 2018 to 2022, BMO Capital forecasts revenue and EPS CAGRs of 5% and 8%,... More
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance
January 24, 2019 7:00 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $0.94, $0.09 better than the analyst estimate of $0.85. Revenue for the quarter came in at $5.97 billion versus the consensus estimate of $5.99 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2019 EPS of $4.10-$4.20, versus the consensus of... More
